Steatohepatitis
Articles tagged with Steatohepatitis
$10 million grant funds research and solutions on ‘forever chemicals’
A $10 million grant from the National Institute of Environmental Health Sciences will support research on PFAS health effects and translate discoveries into real-world solutions. The study aims to identify links between PFAS exposure and metabolic conditions, such as obesity and type 2 diabetes.
Intestinal Candida albicans is associated with subclinical coronary atherosclerosis in metabolic dysfunction-associated steatotic liver disease with cirrhosis
A cross-sectional study found intestinal Candida albicans abundance correlates with subclinical coronary atherosclerosis in metabolic dysfunction-associated steatotic liver disease. Cirrhosis patients showed higher Candida albicans levels and more severe atherosclerosis.
Metabolic risk factors and clinical presentations of metabolic dysfunction-associated steatotic liver disease using data from the all of US research program
Metabolic dysfunction-associated steatotic liver disease (MASLD) affects approximately 32% of the US adult population. Obesity was identified as the strongest independent MRF among Asians, Whites, and Hispanics, particularly in individuals younger than 50 years, whereas hypertension was the strongest independent MRF in Blacks.
How the internal liver clock orchestrates daily fat secretion
A Salk Institute study identifies Fibroblast Growth Factor 1 (FGF1) as the molecular signal that tells the liver when to release fat into the bloodstream, following a precise rhythm timed to the body's internal clock.
Exosomal miR-122-3p identified as key driver of metabolic dysfunction-associated steatotic liver disease
A study identified exosomal microRNA-122-3p as a key driver of MASLD pathogenesis. Elevated miR-122-3p levels induced triglyceride accumulation and reactive oxygen species production in liver cells.
GLP-1 medicine improves liver health independent of weight loss
Researchers have found that semaglutide, an active ingredient in popular weight loss drugs, acts directly on a subset of liver cells to improve organ function and reduce inflammation, scarring, and enzyme levels. This finding challenges traditional assumptions about how GLP-1 medicines work in the liver.
Understanding pathogenesis of liver cirrhosis for improved clinical management
Researchers compare viral and MASLD cirrhosis pathogenic mechanisms, identifying shared pathways and diagnostic differences. The study aims to establish a framework for prevention, diagnosis, treatment, and monitoring of MASLD cirrhosis.
Researchers identify mechanism for body weight-reducing hormone
A hormone called FGF21 reverses obesity in mice by signaling to the hindbrain, a region targeted by GLP-1 drugs. This finding provides insight into the naturally occurring hormone's benefits for weight loss and MASH treatment.
Role of uric acid in steatotic liver disease pathogenesis
Elevated uric acid promotes liver damage and disease severity through inflammation, oxidative stress, and metabolic disturbances. Lifestyle interventions, medications, and potential biomarkers are being explored to improve diagnostic efficacy and treatment.
New research identifies potential treatment target in fatty liver disease
A new study has identified an altered expression of specific genes in individuals with obesity, metabolic dysfunction-associated steatotic liver disease (MASLD), and liver fibrosis. The research team found that inhibiting the gene expression can reduce liver fibrosis, offering a potential new treatment option.
Bidirectional regulation between metabolic dysfunction-associated steatotic liver disease and sarcopenia via liver-muscle crosstalk
This study reveals a bidirectional causal link between MASLD and sarcopenia, mediated by liver-muscle communication. Altered pathways in both liver and muscle tissues contribute to the development of these conditions.
TF-rs1049296 C>T variant modifies the association between hepatic iron stores and liver fibrosis in metabolic dysfunction-associated steatotic liver disease
A study found that the TF-rs1049296 C>T variant is associated with a higher risk of significant liver fibrosis in patients with MASLD, particularly in those with RES iron deposition. The variant was also linked to increased risk of SF in mixed hepatocellular/RES iron deposition patterns.
Applications of artificial intelligence and smart devices in metabolic dysfunction-associated steatotic liver disease
This review synthesizes current applications of AI and smart devices in MASLD care, discussing their benefits and limitations. AI models leverage EHR, laboratory data, and multi-omics information to predict risk and severity, while also enhancing medical imaging interpretation and liver histopathology assessment.
Oxytocin attenuates metabolic dysfunction-associated steatotic liver disease via AMPK/SREBP1c/FAS-mediated suppression of hepatic lipogenesis
Researchers investigated the therapeutic potential and molecular mechanisms of oxytocin in metabolic dysfunction-associated steatotic liver disease (MASLD). Oxytocin attenuates lipid accumulation and accelerates lipid metabolism by regulating the AMPK/SREBP1c/FAS axis.
Nutrient-stimulated hormone-based therapies: A new frontier in the prevention and management of MASH-associated hepatocellular carcinoma
Nutrient-stimulated hormone-based therapies (NuSHs) show promise in managing MASH and preventing HCC progression. NuSHs improve metabolic parameters, reduce liver fat and fibrosis, and modulate immune-metabolic pathways that drive hepatocarcinogenesis.
Research progress on leptin in metabolic dysfunction-associated fatty liver disease
Research on leptin reveals its multifaceted roles in MAFLD, including regulation of energy balance and metabolism. Leptin therapy shows promise in rare cases of leptin deficiency but is largely ineffective in obesity-associated hyperleptinemia.
The role of hepatic SIRT1: From metabolic regulation to immune modulation and multi-target therapeutic strategies
This review highlights SIRT1 as a key regulator in MASLD, orchestrating metabolic homeostasis, immune modulation, and inter-organ communication. SIRT1's therapeutic potential is supported by natural product activators and synthetic small-molecule compounds.
Mapping metabolic dysfunction-associated steatotic liver disease models of care across 17 Middle East and North Africa countries: Insights into guidelines, infrastructure, and referral systems
This study reveals limited national strategies, weak guideline implementation, and underutilized multidisciplinary collaboration in MASLD care across the MENA region. The insights gathered from regional experts highlight systemic challenges and actionable opportunities for improvement.
Arctigenin prevents metabolic dysfunction-associated steatohepatitis by inhibiting NLRP3/GSDMD-N axis in macrophages
Arctigenin, a monomer of Fructus Arctii, exhibits anti-inflammatory activity and prevents MASH progression through modulating the NLRP3/GSDMD-N axis in macrophages. ATG administration also reduces hepatic macrophage infiltration, serum enzyme levels, and lipid peroxidation while enhancing antioxidant enzyme activity.
Urinary arsenic exposure and metabolic dysfunction-associated steatotic liver disease
This study found a significant association between urinary arsenic levels and the prevalence of metabolic dysfunction-associated steatotic liver disease. Higher arsenic exposure was linked to an increased risk of MASLD, particularly in females and individuals with higher incomes.
USC Superfund researchers identify “forever chemical” PFHpA as risk factor for severe liver disease in adolescents
Researchers identified a significant association between perfluoroheptanoic acid (PFHpA) exposure and metabolic dysfunction-associated steatotic liver disease (MASLD) in adolescents. The study used advanced models to reveal PFHpA's role in disrupting biological pathways, leading to liver damage and inflammation.
Breakthrough 3D dynamic cell models revolutionize MASLD research
Researchers developed innovative 3D dynamic cell co-culture models to simulate MASLD progression stages, addressing traditional 2D culture limitations. Pro-inflammatory macrophages were identified as drivers of hepatocyte lipid metabolism disruption.
Safer, more effective vaccines with new mRNA vaccine technology
Researchers have developed a new mRNA vaccine technology using albumin-recruiting lipid nanoparticles to deliver vaccines precisely to lymph nodes, avoiding liver toxicity. The approach outperformed traditional delivery systems in laboratory tests, producing strong antitumor T-cell responses and high levels of neutralizing antibodies.
Co-designing approaches to sustainable exercise care for people with metabolic dysfunction-associated steatotic liver disease
People with MASLD emphasize affordability, accessibility and considerations for comorbidities in exercise care. Exercise-focused research should include standardized non-invasive outcomes and culturally responsive models to advance awareness and management of MASLD.
Biomarker discovery for metabolic dysfunction-associated steatotic liver disease utilizing Mendelian randomization, machine learning, and external validation
A study discovered six causal molecular biomarkers (CNPY4, ENTPD6, HLA-A) and eight clinical biomarkers for metabolic dysfunction-associated steatotic liver disease (MASLD). Serum total protein levels partially mediated the effect of HLA-A on MASLD.
Urinary arsenic exposure and metabolic dysfunction-associated steatotic liver disease
This study found a significant association between arsenic exposure and MASLD in humans, with higher urinary arsenic levels increasing the risk ofMASLD. The analysis also showed that arsenic exposure persisted across key subgroups, suggesting its contribution to hepatic steatosis even at moderate exposure levels.
Assessment of metabolic dysfunction-associated steatotic liver disease and liver fibrosis: A cross-sectional study in asymptomatic individuals in greater vancouver
A substantial proportion of asymptomatic individuals in Greater Vancouver have undetected MASLD and significant fibrosis. Age, male sex, ethnicity, cardiac disease, diabetes, hypertension, and obesity were significantly associated with fibrosis.
UofL research shows combined exposure to alcohol and “forever chemicals” increases liver damage
A study from University of Louisville researchers found that perfluorooctane sulfonate (PFOS) can worsen liver damage when combined with alcohol consumption. The study showed that PFOS exposure can increase fat accumulation and markers of liver damage, disrupt the liver's ability to manage fats, and activate pathways that promote liver...
Orphan nuclear receptors in metabolic dysfunction-associated steatotic liver disease development
This review explores the roles of orphan nuclear receptors (ONRs) in metabolic dysfunction-associated steatotic liver disease (MASLD) pathogenesis. ONRs modulate key pathways involved in lipid metabolism, inflammation, and fibrosis, offering novel therapeutic avenues.
Short-term physical activity reduces metabolic-associated steatohepatitis by promoting the degradation of branched-chain amino acids in skeletal muscle
Researchers discovered that short-term physical activity decreases liver disease severity by breaking down branched-chain amino acids in skeletal muscle. This process enhances redox balance and inhibits lipid accumulation in hepatocytes.
Leading cancer and metabolic disease expert Michael Karin joins Sanford Burnham Prebys
Michael Karin, renowned for his work on chronic inflammation and cancer, will lead the Center for Metabolic and Liver Diseases at Sanford Burnham Prebys. He aims to develop new treatments for metabolic and liver diseases, which affect millions of patients worldwide.
Scientific community urges greater action against the silent rise of liver diseases
Chronic liver diseases like MASLD and MASH affect 33% and 5% of adults worldwide, respectively. Experts propose doubling MASH diagnosis rate by 2027 to improve outcomes and reduce healthcare burdens. A paradigm shift towards preventive hepatology is key to addressing this growing public health threat.
Advances in novel drug therapy for metabolic dysfunction-associated steatohepatitis cirrhosis
Clinical trials for MASH cirrhosis have shown promising results, particularly with FGF21 analogues like efruxifermin and pegozafermin. The review emphasizes the need for effective interventions targeting advanced disease stages and highlights the importance of surrogate endpoints in accelerating approvals.
Research shows how hormone can reverse fatty liver disease
Researchers at the University of Oklahoma discovered that FGF21 can reverse fatty liver disease in mice by sending signals to both the brain and liver. The study provides valuable insight into the mechanism of action of FGF21, a target for a new class of highly anticipated drugs.
Intestinal depletion of TM6SF2 exacerbates high-fat diet-induced metabolic dysfunction-associated steatotic liver disease through the gut-liver axis
This study found that intestinal depletion of TM6SF2 exacerbates high-fat diet-induced MASLD by altering the gut microbiota and liver lipid content. The absence of TM6SF2 also led to increased serum biomarkers associated with MASLD progression.
Semaglutide treats liver disease in two thirds of patients
New research published in the New England Journal of Medicine shows that semaglutide effectively treats liver disease in two-thirds of patients with MASH. The substance has been found to halt and even reverse the disease, reducing steatohepatitis and improving liver fibrosis.
VCU-led research highlights semaglutide’s potential for treating fatty liver disease
A VCU-led study suggests that semaglutide, a medication approved for weight loss and blood sugar control, may also reverse liver damage in patients with non-cirrhotic non-alcoholic steatohepatitis (MASH). Researchers found that nearly 90% of participants remained on the medication after 72 weeks without significant side effects.
Children with liver disease face dramatically higher risk of early death
A study published in Hepatology reveals that children with metabolic dysfunction-associated steatotic liver disease (MASLD) are at a significantly increased risk of premature death and serious long-term health complications. The mortality rate was found to be nearly 40 times higher than the national average.
Drug candidate successfully treats atherosclerosis, fatty liver disease in large mammals
Researchers successfully treated atherosclerosis and fatty liver disease using DT-109 in nonhuman primates, which has potential as a dual therapy for two common conditions. The compound reduced the formation of atherosclerotic plaques and stopped critical processes that lead to vascular calcification.
Ursolic acid modulates estrogen conversion to relieve inflammation in metabolic dysfunction-associated steatotic liver disease via HSD17B14
Researchers investigated the therapeutic mechanisms of ursolic acid on metabolic dysfunction-associated steatotic liver disease. Ursolic acid was found to reduce inflammation by modulating estrogen conversion via HSD17B14, a crucial enzyme regulating estrogen balance.
Mother’s high-fat diet can cause liver stress in fetus, study shows
A new study published in Liver International found that a mother's high-fat diet during pregnancy can lead to liver stress and changes in the fetus's bile acid levels. This may be a key factor in the development of metabolic dysfunction-associated steatotic liver disease (MASLD) later in life.
Nwd1 gene deletion triggers MASH-like pathology in mice: a new scientific breakthrough
The study highlights the role of the Nwd1 gene in liver disease and its potential as a therapeutic target. Mice with Nwd1 gene deletion exhibited liver pathologies mirroring MASH, including excessive lipid accumulation and increased ER stress.
Researchers identify a gene to guide novel therapeutics of nonalcoholic fatty liver diseases
The study highlights the significant protective role of Asah1 in preventing NAFLD progression by regulating hepatic lipid homeostasis and cellular maintenance processes. The findings suggest that targeting Asah1 expression or activity may inform new therapeutic strategies for improving patient outcomes.
New drug shows promise in treating liver disease caused by metabolic dysfunction, cancer
A new drug candidate has been developed to target and eliminate senescent cells in the liver, reducing fat buildup and preventing liver damage. The study demonstrates a safer and more effective approach to treating metabolic dysfunction-associated steatotic liver disease (MASLD) and potentially inhibiting liver cancer development.
Clusters of metabolic dysfunction-associated steatotic liver disease for precision medicine
Research identifies six clusters of metabolic dysfunction-associated steatotic liver disease (MASLD) with varying pathophysiology and clinical outcomes. These clusters may enable personalized risk prognosis and treatment through lifestyle modification programs and targeted therapies.
Unlocking the role of long non-coding RNAs in liver disease progression
Long non-coding RNAs (lncRNAs) play a critical role in metabolic and fibrotic pathways, influencing lipid metabolism, inflammation, apoptosis, and fibrogenesis. Targeting pathogenic lncRNAs or enhancing protective ones may provide a dual approach for MASLD treatment.
The role of solute carrier family transporters in hepatic steatosis and hepatic fibrosis
SLC transporters contribute to the development of hepatic steatosis by regulating lipid metabolism, particularly with SLC2A2, GLUT4, and GLUT5. These proteins influence processes like de novo lipogenesis and insulin resistance in hepatocytes.
Chinese Medical Journal review highlights senescence’s dual role in liver disease and emerging therapies
Researchers reveal senescence's impact on liver health, from repair and regeneration to chronic disease progression. Emerging therapies, such as senolytic treatments, aim to selectively eliminate senescent cells while preserving healthy tissue.
SOX9 overexpression ameliorates metabolic dysfunction-associated steatohepatitis through activation of the AMPK pathway
This study investigates SOX9's role in MASH pathogenesis and explores its underlying mechanisms. SOX9 overexpression alleviates hepatic lipid accumulation by activating the AMPK pathway.
The complexities of hepatic SLC7A11 to promote MASLD mediated by nonessential amino acids
Overexpressing hepatic SLC7A11 leads to glutamate and serine deficiency, promoting MASLD progression through ferroptosis. Serine supplementation rescues the disease phenotype.
Heterogeneity of metabolic dysfunction-associated steatotic liver disease
Researchers have identified three major pathomechanisms of MASLD: hepatic genetic component, metabolic de novo lipogenesis, and adipose tissue dysfunction. These subtypes have distinct risk factors for cardiovascular disease and type 2 diabetes. Novel pharmacological approaches may facilitate targeted therapies for each subtype.
A simple plasma-based biomarker could predict liver fibrosis in Latino adolescents with obesity
Researchers discovered a novel combination of plasma-based biomarkers that can predict liver fibrosis in Latino adolescents with obesity. The study found that dihydroxyacetone phosphate (DHAP) and alanine transaminase (ALT) were significantly associated with fibrosis, suggesting a potential low-cost, noninvasive screening tool.
Current status of glucagon-like peptide-1 receptor agonists in metabolic dysfunction-associated steatotic liver disease: A clinical perspective
GLP-1RAs improve liver histology, reduce liver fat, and enhance metabolic parameters in MASLD patients. However, challenges remain in assessing long-term liver benefits and clarifying the effects on liver fibrosis.
MASH discovery redefines subtypes with distinct risks: shaping the future of fatty liver disease treatment
A new study has identified two distinct subtypes of metabolic dysfunction-associated steatotic liver disease (MASH) with similar histological features but different clinical outcomes. The research empowers clinicians to adopt subtype-specific treatments leveraging simple clinical markers, offering a clear path to improve patient outcomes.
Broken sleep a hallmark sign of living with the most common liver disease, scientists find
A new study proves a suspected link between poor sleep and MASLD, a liver disorder that affects 30% of adults. Patients with MASLD experience significant sleep fragmentation, waking up 55% more often at night.
AI finds undiagnosed liver disease in early stages
A new study reveals that an AI algorithm can accurately detect early-stage metabolic-associated steatotic liver disease (MASLD) in patients who meet the criteria, leaving 83% undiagnosed. This highlights the need for improved screening and diagnosis methods to prevent progression to advanced liver disease.
Decoding 17-beta-hydroxysteroid dehydrogenase 13: A multifaceted perspective on its role in hepatic steatosis and associated disorders
The 17-beta-hydroxysteroid dehydrogenase 13 gene plays a significant role in regulating liver lipid metabolism, with loss-of-function variants linked to reduced risk of chronic liver disease progression. HSD17B13 modulation may provide therapeutic benefits for individuals with metabolic liver disease.
Advanced liver fibrosis predicts liver outcomes in biopsy-proven metabolic dysfunction-associated steatotic liver disease
A U.S.-based single-center retrospective cohort study found that advanced liver fibrosis is a primary risk factor for incident liver decompensation and liver-related events in patients with biopsy-proven metabolic dysfunction-associated steatotic liver disease. The study, published in the Journal of Clinical and Translational Hepatolog...
Transcriptomic landscape analysis reveals a persistent DNA damage response in metabolic dysfunction-associated steatohepatitis post-dietary intervention
Metabolic dysfunction-associated steatohepatitis (MASLD) exhibits persistent activation of the DNA damage response (DDR) and its primary transcription factor P53 even after dietary reversal. Elevated P53 levels correlate with hepatocyte ballooning, suggesting a link between DDR signaling and MASLD recurrence.